GLP-1 Receptor Agonists: What You Need to Know
GLP-1 receptor agonists like liraglutide (Ozempic) and tripeptide (Mounjaro) can cause gastrointestinal issues such as nausea, vomiting, diarrhoea, and abdominal pain They may also lead to pancreatitis, biliary disease, and hypersensitivity reactions, including anaphylaxis Renal problems can occur, especially with severe GI losses When combined with sulfonylureas or insulin, there’s a higher risk of hypoglycemia Semaglutide has been linked to an increased risk of diabetic retinopathy. However, cardiovascular trials show no increased risk of acute pancreatitis or pancreatic cancer Interestingly, a Scandinavian study found GLP-1 RAs reduce serious renal events compared to DPP-4 inhibitors The American College of Cardiology notes potential gallbladder disease and heart rate increases